JP7515567B2 - 生物医薬組成物及び関連する方法 - Google Patents

生物医薬組成物及び関連する方法 Download PDF

Info

Publication number
JP7515567B2
JP7515567B2 JP2022506976A JP2022506976A JP7515567B2 JP 7515567 B2 JP7515567 B2 JP 7515567B2 JP 2022506976 A JP2022506976 A JP 2022506976A JP 2022506976 A JP2022506976 A JP 2022506976A JP 7515567 B2 JP7515567 B2 JP 7515567B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543273A (ja
Inventor
ジェームズ、ケイ．クランツ
マイケル、ジョセフ、モロイ
ジョセフ、ブイ．リネッラ、ジェイアール．
エリザベス、レイ、シュミット
ヒラリー、アンバー、シュスラー
テハシュ、シャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71994687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7515567(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2022543273A publication Critical patent/JP2022543273A/ja
Priority to JP2024016653A priority Critical patent/JP2024056791A/ja
Application granted granted Critical
Publication of JP7515567B2 publication Critical patent/JP7515567B2/ja
Priority to JP2025137331A priority patent/JP2025186256A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2022506976A 2019-08-06 2020-07-31 生物医薬組成物及び関連する方法 Active JP7515567B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024016653A JP2024056791A (ja) 2019-08-06 2024-02-06 生物医薬組成物及び関連する方法
JP2025137331A JP2025186256A (ja) 2019-08-06 2025-08-20 生物医薬組成物及び関連する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962883451P 2019-08-06 2019-08-06
US62/883,451 2019-08-06
US201962948432P 2019-12-16 2019-12-16
US62/948,432 2019-12-16
US202062984110P 2020-03-02 2020-03-02
US62/984,110 2020-03-02
PCT/IB2020/057267 WO2021024133A2 (en) 2019-08-06 2020-07-31 Biopharmacuetical compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024016653A Division JP2024056791A (ja) 2019-08-06 2024-02-06 生物医薬組成物及び関連する方法

Publications (2)

Publication Number Publication Date
JP2022543273A JP2022543273A (ja) 2022-10-11
JP7515567B2 true JP7515567B2 (ja) 2024-07-12

Family

ID=71994687

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022506976A Active JP7515567B2 (ja) 2019-08-06 2020-07-31 生物医薬組成物及び関連する方法
JP2024016653A Pending JP2024056791A (ja) 2019-08-06 2024-02-06 生物医薬組成物及び関連する方法
JP2025137331A Pending JP2025186256A (ja) 2019-08-06 2025-08-20 生物医薬組成物及び関連する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024016653A Pending JP2024056791A (ja) 2019-08-06 2024-02-06 生物医薬組成物及び関連する方法
JP2025137331A Pending JP2025186256A (ja) 2019-08-06 2025-08-20 生物医薬組成物及び関連する方法

Country Status (16)

Country Link
US (1) US20220289859A1 (https=)
EP (1) EP4010372A2 (https=)
JP (3) JP7515567B2 (https=)
KR (1) KR20220041915A (https=)
CN (2) CN114502593A (https=)
AU (1) AU2020325753B2 (https=)
BR (1) BR112022002236A2 (https=)
CA (1) CA3146471A1 (https=)
CL (1) CL2022000294A1 (https=)
CO (1) CO2022002627A2 (https=)
IL (1) IL290325A (https=)
MX (1) MX2022001626A (https=)
NZ (1) NZ784975A (https=)
PH (1) PH12022550277A1 (https=)
TW (2) TWI867020B (https=)
WO (1) WO2021024133A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202323822A (zh) * 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 生藥組合物及穩定同位素標記肽之圖譜定位方法
TW202413435A (zh) * 2022-08-05 2024-04-01 美商艾力克森製藥公司 融合蛋白的藥物組成物及其使用方法
EP4630454A1 (en) 2022-12-05 2025-10-15 GlaxoSmithKline Intellectual Property Development Ltd Methods of treatment using b-cell maturation antigen antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520088A (ja) 2011-05-27 2014-08-21 グラクソ グループ リミテッド Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA033110B1 (ru) 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
JP6694712B2 (ja) 2012-11-01 2020-05-20 マックス−デルブルック−セントラム フアー モレキュラーレ メデジン Ｃｄ２６９（ｂｃｍａ）に対する抗体
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
CN105209076A (zh) 2013-03-15 2015-12-30 阿布维公司 抗体药物偶联物(adc)纯化
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
WO2015077605A1 (en) 2013-11-25 2015-05-28 Seattle Genetics, Inc. Preparing antibodies from cho cell cultures for conjugation
WO2015158671A1 (en) 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP6285274B2 (ja) 2014-04-28 2018-02-28 株式会社ブリヂストン バイアスタイヤ及びその製造方法
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR20240135036A (ko) 2014-12-05 2024-09-10 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
PL3988117T3 (pl) * 2015-04-13 2025-03-10 Pfizer Inc. Przeciwciała terapeutyczne i ich zastosowania
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
EP3147954A1 (en) 2015-09-22 2017-03-29 Nokia Technologies Oy Photodetector with conductive channel made from two dimensional material and its manufacturing method
US20200254093A1 (en) * 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
CA3079215A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520088A (ja) 2011-05-27 2014-08-21 グラクソ グループ リミテッド Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drug Discovery Today，2017年，22(10)，1547-1556
薬剤学，2014年，74(1)，39-46

Also Published As

Publication number Publication date
CA3146471A1 (en) 2021-02-11
JP2022543273A (ja) 2022-10-11
CN120204384A (zh) 2025-06-27
TWI867020B (zh) 2024-12-21
MX2022001626A (es) 2022-03-02
PH12022550277A1 (en) 2022-11-21
AU2020325753B2 (en) 2025-03-13
IL290325A (en) 2022-04-01
EP4010372A2 (en) 2022-06-15
US20220289859A1 (en) 2022-09-15
WO2021024133A2 (en) 2021-02-11
TW202120549A (zh) 2021-06-01
CL2022000294A1 (es) 2022-10-07
KR20220041915A (ko) 2022-04-01
JP2025186256A (ja) 2025-12-23
AU2020325753A1 (en) 2022-03-03
NZ784975A (en) 2025-10-31
BR112022002236A2 (pt) 2022-05-03
TW202227142A (zh) 2022-07-16
CN114502593A (zh) 2022-05-13
JP2024056791A (ja) 2024-04-23
WO2021024133A3 (en) 2021-03-25
CO2022002627A2 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
US20200268901A1 (en) Antibodies comprising modified heavy constant regions
AU2018272852B2 (en) Antibodies comprising modified heavy constant regions
JP2024056791A (ja) 生物医薬組成物及び関連する方法
US20220106400A1 (en) Antibodies comprising modified heavy constant regions
CN117396513A (zh) 治疗癌症的联合疗法
RU2824761C2 (ru) Биофармацевтические композиции и связанные с ними способы
US20240369568A1 (en) Biopharmaceutical Compositions and Stable Isotope Labeling Peptide Mapping Method
CN118159294A (zh) 用于治疗癌症的联合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240702

R150 Certificate of patent or registration of utility model

Ref document number: 7515567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153